Skip to main content
. Author manuscript; available in PMC: 2016 Dec 15.
Published in final edited form as: Clin Cancer Res. 2015 Aug 3;21(24):5612–5618. doi: 10.1158/1078-0432.CCR-15-0789

Figure 2.

Figure 2

Overall survival (A) and Disease-free survival (B) by GSK3β expression. The 3-yr. OS rates for GSK3β ≤ Q3 vs. GSK3β > Q3 were 16% (95% CI: 10%–23%) and 30% (95% CI: 17%–44%), respectively [log rank p-value=0.0082]. The 3-yr. DFS rates for those with GSK3β ≤ Q3 and GSK3β >Q3, were 9% (95% CI: 5%–15%) and 20% (95% CI: 9%–33%) respectively [log-rank p-value =0.0081].